{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:56:28Z","timestamp":1789394188199,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Reports of septic transfusion reactions (STRs) after transfusion of culture\u2010negative platelets (PLTs) justify more effective prevention strategies. Pathogen reduction technologies or performance of additional point\u2010of\u2010issue testing are proposed strategies to enhance safety through Day 5 of storage.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>Trima leukoreduced apheresis PLTs (APs) were collected during two study periods (45 and 31 months) using standard procedures, with target settings adjusted during the second period to maintain split rate after increased culture volume. Primary testing for bacterial contamination was performed using BacT\/ALERT 3D with sampling from the mother bag 24 to 36 hours after collection. Two culture approaches were compared: in Period\u00a0A, an 8\u2010mL sample in one aerobic culture bottle (CB), and in Period\u00a0B a minimal proportional sample volume (PSV) of at least 3.8% of mother bag volume into one to three aerobic CBs (7\u201010 mL per bottle).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>In Periods A and B, 188,389 and 159,098 AP collections were tested, respectively. The true\u2010positive (TP) rate in Period\u00a0A was 0.90 per 10,000 collections and in Period B was 1.83 per 10,000 (p\u00a0&lt;\u00a00.05). In Period\u00a0B, 12 of 29 (41%) TP results had discrepant CB results (DCBRs; at least one of multiple bottles without growth). The false\u2010positive rate in Period\u00a0B, 15.05 per 10,000 collections, was significantly higher than that of Period\u00a0A, 3.66 per 10,000. One contaminated collection resulting in STR(s) was reported in each study period. Implementation of PSV was operationally successful and did not impact the AP split rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Proportional sample volume improved the sensitivity of primary testing and identified collections that could have escaped detection had only a single bottle with 8\u2010 to 10\u2010mL volume been used. PSV may represent another approach to enhanced PLT safety for 5\u2010day storage without a requirement for secondary testing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14198","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T03:40:41Z","timestamp":1498189241000},"page":"2413-2419","source":"Crossref","is-referenced-by-count":21,"title":["Improved yield of minimal proportional sample volume platelet bacterial culture"],"prefix":"10.1111","volume":"57","author":[{"given":"Hany","family":"Kamel","sequence":"first","affiliation":[{"name":"Blood Systems, Inc Scottsdale Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Townsend","sequence":"additional","affiliation":[{"name":"Blood Systems, Inc Scottsdale Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Bravo","sequence":"additional","affiliation":[{"name":"Blood Systems, Inc Scottsdale Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph R.","family":"Vassallo","sequence":"additional","affiliation":[{"name":"Blood Systems, Inc Scottsdale Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02460.x"},{"key":"e_1_2_8_3_1","unstructured":"Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2015 [Internet].Silver Spring (MD):U.S. Food and Drug Administration;2015[cited 2017 Mar 19]. Available from:https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/SafetyAvailability\/ReportaProblem\/TransfusionDonationFatalities\/UCM518148.pdf."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01550.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03708.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500154"},{"key":"e_1_2_8_7_1","unstructured":"Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. Draft guidance for industry [Internet].2016Mar [cited 2017 Mar 17]. Available from:https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/UCM425952.pdf."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00978.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01763.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03489.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13107"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03821.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12148"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12410"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03308.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-655944"},{"key":"e_1_2_8_17_1","first-page":"61","article-title":"One million and counting: bacterial screening of platelet components by NHSBT, is it an effective risk reduction measure?","volume":"109","author":"McDonald C","year":"2015","journal-title":"Vox Sang"},{"key":"e_1_2_8_18_1","first-page":"28A","article-title":"Improved bacterial culture of platelet product: preliminary results after implementation of a two\u2010bottle system with 48\u2010hour sampling","volume":"56","author":"Delage G","year":"2016","journal-title":"Transfusion"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01132.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02192.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03187.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12225"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2008.01051.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2010.01037.x"},{"key":"e_1_2_8_25_1","unstructured":"Annual SHOT report [Internet].Manchester:SHOT Office;2015[cited 2017 Mar 17]. Available from:https:\/\/www.shotuk.org\/wp-content\/uploads\/SHOT-2015-Annual-Report-Web-Edition-Final-bookmarked-1.pdf."}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.14198","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:59:57Z","timestamp":1694015997000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/trf.14198"],"URL":"https:\/\/doi.org\/10.1111\/trf.14198","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}